PVLA Palvella Therapeutics, Inc.
Healthcare$117.59+3.16%ClosedMarket Cap: $1.39B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
6.42
P/S
0.00
EV/EBITDA
-34.03
DCF Value
$4.71
FCF Yield
-2.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-56.9%
ROA
-18.7%
ROIC
-17.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-14.9M | $-15.8M | $— | — |
| Q4 null | $0.00 | NaN% | $-11.3M | $-12.7M | $— | — |
| FY null | $0.00 | NaN% | $-38.6M | $-41.7M | $— | — |
| Q3 null | $0.00 | NaN% | $-10.2M | $-11.3M | $— | — |
| Q2 null | $0.00 | NaN% | $-9.3M | $-9.5M | $— | — |
| Q1 null | $0.00 | NaN% | $-7.9M | $-8.2M | $— | — |
| Q4 null | $0.00 | NaN% | $-4.4M | $-4.0M | $— | — |
| FY null | $0.00 | NaN% | $-14.1M | $-17.4M | $— | — |
| Q3 null | $0.00 | NaN% | $-5.1M | $-6.8M | $— | — |
| Q2 null | $0.00 | NaN% | $-2.9M | $-4.2M | $— | — |
| Q1 null | $0.00 | NaN% | $-1.8M | $-2.5M | $— | — |
| Q4 2023 | $1.3M | 100.0% | $-5.5M | $-4.6M | $-3.71 | — |